

ABBVIE LTD ABPI DISCLOSURE REQUIREMENTS ON TRANSFERS OF VALUE TO PATIENT ORGANISATIONS FOR FINANCIAL YEAR 2022

Name of Patient Organisation	Financial Support	Fee	Expenses	Category	Short Description of Support Activity (Objective)
The Arthritis and Musculoskeletal Alliance	£7,500			Sponsorship	Annual associate membership for 2022
Axial Spondyloarthritis International	£25,000			Sponsorship	Sponsorship of Axial Spondyloarthritis International Meeting
Bliss	£5,000			Grant	Core funding to support educational materials
Cancer 52	£10,000			Sponsorship	Corporate membership
Chronic Lymphocytic Leukaemia Support Association	£12,000			Grant	Funding for 2022 chronic lymphocytic leukaemia patient education and empowerment project
Ciannas Smile	£5,300			Grant	Funding towards 2022 health and wellbeing project to develop, produce and share information and resources on sickle cell disease
Dementia UK	£5,000			Grant	Funding to support vital infrastructure component of the National Helpline - Puzzle

Name of Patient Organisation	Financial Support	Fee	Expenses	Category	Short Description of Support Activity (Objective)
Eczema Outreach		£360	£438	Service	Speaking at meeting for UK parliamentarians on the topic of atopic dermatitis
Eczema Outreach	£30,000			Grant	Core funding for 2022
GMFA (trading as LGBT HERO)	£6,339			Grant	Funding to run a social support programme aimed to tackle the high levels of isolation and loneliness experienced by people living with HIV. GMFA is a 'sexual wellbeing project for gay, bi and trans men'
Hepatitis C Trust	£25,000			Sponsorship	Funding for the 2022 Hepatitis C virus Action programme of work
Leukaemia Care	£15,000			Grant	Acute myeloid leukaemia patient support
Lev Echod Cancer Care	£1,200			Grant	Funding towards the Health Hub health spa to benefit cancer patients on a regular basis free of charge
London Joint Working Group on Substance use and Hepatitis C c/o ADFAM	£11,500			Sponsorship	Funding to support the planning and delivery of 2022 Annual Conference
Lymphoma Action	£10,000			Grant	Education programmes for people affected by lymphoma
National Eczema Society		£360		Service	Speaking at meeting for UK parliamentarians on the topic of atopic dermatitis
Myeloma UK	£10,000			Grant	Funding for 'Empowering patients with accessible patient health information' project
The Migraine Trust			£227	Service	Regional Roundtable Meeting - advisory and speaker services
National Axial Spondyloarthritis Society	£30,000			Grant	Rheumatology service improvement programme - Aspiring to Excellence
National Axial Spondyloarthritis Society		£400		Service	Speaking at an AbbVie meeting on the topic of Ankylosing Spondyloarthritis
National Eczema Society	£20,000			Sponsorship	Core funding for 2023 membership
National Rheumatoid Arthritis Society*	£10,000			Grant	Additional Core Funding 2021
National Rheumatoid Arthritis Society	£10,000			Grant	Partial project funding towards 'Enhanced Right Start'
Neurological Alliance	£11,030			Sponsorship	Annual membership of the Industry Reference Group
Neurological Alliance			£207	Service	Regional Roundtable Meeting - advisory and speaker services
Parkinson's Europe	£42,003			Sponsorship	2022 membership of Parkinson's Europe
Parkinson's Europe		£1,190		Service	Consulting on research projects in the area of neuroscience

Name of Patient Organisation	Financial Support	Fee	Expenses	Category	Short Description of Support Activity (Objective)
Patients Association	£15,000			Grant	Core funding for 2022
Psoriasis Association	£8,000			Grant	Funding towards 2022-23 Psoriasis Association's charitable activity supporting patients
Psoriasis Association	£2,500			Grant	Funding towards Psoriasis Association Annual Conference – 18 June 2022
Retina UK	£4,000			Grant	Partial project funding towards professional and patient conference
Royal National Institute of Blind People	£7,000			Grant	Funding for development of an improved sight loss care pathway
Spinal Muscular Atrophy UK (SMA UK)	£8,676			Grant	Funding towards refreshing the SMA UK visual identity and developing a set of branding guidelines and upgrade their website
Tommys	£10,000			Grant	Funding towards updating behaviour change tools to encourage women to make healthy choices
Waldenstrom's macroglobulinaemia UK (WMUK)	£4,990			Grant	Funding to produce an information booklet for people newly diagnosed with Waldenstrom's macroglobulinaemia

*National Rheumatoid Arthritis Society included this financial support in its 2021 disclosures (based on contracted date), but AbbVie has included this in its 2022 disclosures (based on payment date). This is solely due to different methodologies of the two organisations around disclosures.

Crohn's & Colitis UK will declare financial support from AbbVie for its 'Earlier Diagnosis Programme' within its 2022 disclosures (based on contracted date), but this will be declared by AbbVie in its 2023 disclosures (based on payment date). This is solely due to different methodologies of the two organisations around disclosures.

ABBVIE LTD TRANSPARENCY DISCLOSURE METHODOLOGICAL NOTES FOR REPORTING YEAR 2022

As a member company of EFPIA and ABPI, AbbVie Ltd is committed to ensuring that the nature and scope of partnerships and transfers of value (ToV) to Patient Organisations are clear and transparent to the public. Therefore, AbbVie Ltd has published applicable ToV provided directly or indirectly to Patient Organisations for the 2022 calendar year. This Methodological Note provides guidance on how AbbVie Ltd has recorded and publicly reported this information in accordance with the current edition of the ABPI Code of Practice.

Reporting period/Reportable ToV:

The AbbVie Ltd 2022 disclosure includes applicable ToV during the period between 1st January 2022 and 31st December 2022. The applicable ToV relate to payments made within the disclosure period. Payments made from 1st January 2023 will be considered for the next report.

Allergan Acquisition:

Allergan Ltd. was integrated into the AbbVie Ltd business effective 1st April 2022 and therefore Allergan Ltd. payments made from 1st April 2022 have been included in the 2022 AbbVie disclosure.

Allergan Ltd. payments made between 1st January 2022 and 31st March 2022 have been disclosed under Allergan Ltd.

Defining Reportable Organisations:

The ABPI definition of Patient Organisations is broad, so additional factors were taken into consideration when determining whether ToV to organisations were reportable under the category of Patient Organisation.

These included but were not limited to the following in relation to a health condition or disability: provision of information and support services, hosting of campaigns and events to raise awareness, involvement in policy activities to improve patient outcomes, community engagement and provision of other support related to patients' healthcare, except where activities were delivered based on AbbVie's confidential contractual obligations in relation to third parties that are not Patient Organisations (e.g., the NHS).

Transparency Acknowledgment from Patient Organisations:

Agreements between AbbVie Ltd and Patient Organisations relating to ToV have included a Transparency section which included notification of AbbVie's Transparency disclosure obligations.

Validation Approach:

AbbVie has conducted a validation exercise with Patient Organisations contained within this reporting period to make them aware of the disclosure and provide an opportunity to verify any ToV.

Cross Border Interactions:

These ToV include engagements between AbbVie affiliates worldwide and UK Patient Organisations where these have occurred. For example, where a Patient Organisation has participated in an AbbVie global supported programme.

ToV Definitions:

Each ToV includes a category label and brief description of the activity it relates to. The category and associated descriptors are as follows:

- Financial Support, including Grants and Sponsorships:
 - Definition: Funding provided by AbbVie, in whole or in part, for activities carried out by the patient organisation, including project-specific or core funding
 - Examples: Disease awareness campaigns, educational material development, webinars/events, etc.

The key difference between the provision of a grant and sponsorship is that, in the case of grants, AbbVie provides arm's length funding without involvement in the activities or the development of any associated materials, and doesn't receive any goods or services in return.

- Services:
 - Definition: Services provided by the patient organisation to AbbVie, including fees and expenses in relation to the services delivered
 - Examples: Participation in or speaking at an AbbVie meeting or Advisory Board, review of AbbVie materials for patients, etc.

Fees and expenses have been disclosed separately. This includes expenses such as transport or accommodation costs incurred to take part in the associated activity, including those activities that were reimbursed or paid directly by AbbVie.

Value Added Tax (VAT):

Where applicable, disclosure of payments does not include VAT.

Currency:

All information is reported in Pound Sterling (GBP).

Exchange Rate:

Where ToV were captured in foreign currency, amounts were converted to local currency based on AbbVie Ltd Treasury Monthly Average Rates.

Multiyear Contracts:

Activities with ToV crossing calendar years may have the contracted full amount disclosed using the date of last payment.

Post Publication Disputes:

AbbVie will review and investigate disputes with Patient Organisations relative to our disclosures. Any changes resulting from this review will be published in an updated report.